Risperidone: an analysis of the first three years in general use

Area of Science:

• Pharmacology and Psychiatry
• Clinical Neuroscience

Background:

• Risperidone, a serotonin-dopamine antagonist, was introduced in 1993.
• Extensive clinical experience (over 12 million patient-months) has been accumulated.
• Previous studies focused on specific patient groups, necessitating broader efficacy confirmation.

Purpose of the Study:

• To confirm the efficacy of risperidone in diverse schizophrenia patient populations.
• To evaluate risperidone's effectiveness in first-episode and treatment-resistant schizophrenia.
• To assess long-term benefits, side effect profile, and impact on negative symptoms and hospitalization.

Main Methods:

• Analysis of pivotal clinical trials and subsequent studies, including first-episode schizophrenia trials.
• Prospective comparison with clozapine and subanalysis of the North American Trial for treatment-resistant cases.
• Meta-analysis of seven clinical trials for negative symptom efficacy and long-term open-label studies.

Main Results:

• Risperidone demonstrated efficacy across a broad range of schizophrenia patients, including first-episode and treatment-resistant cases.
• Lower doses are suggested for first-episode patients compared to chronic schizophrenia.
• Efficacy against negative symptoms was confirmed; long-term use showed sustained benefits with low extrapyramidal side effect liability, leading to reduced relapse rates and inpatient days. Annual incidence of tardive dyskinesia was 0.3% with risperidone vs. 5-10% with conventional neuroleptics.

Conclusions:

• Risperidone offers significant therapeutic advantages for schizophrenia patients.
• Its favorable side effect profile may improve treatment adherence and long-term outcomes.
• Mental health professionals should anticipate improved treatment outcomes for schizophrenia with risperidone.